European pharma companies warned the European Commission president at a meeting on Tuesday that U.S. tariffs would expedite ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Leading pharmacy benefit managers are shifting away from lucractive rebates on biologic drugs and toward lower-cost ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Tertiary lymphoid structures (TLS) are increasingly recognized to have roles in cancer. Within tumor microenvironments (TME), TLS can arise as ectopic lymphoid organs containing aggregates of ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Children with SMA in the U.K. can switch treatments based on practical needs and preferences without unexpected disease ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...